Compugen (CGEN) Consolidated Net Income (2009 - 2026)
Compugen's (CGEN) quarterly Consolidated Net Income came in at $7.7 million in Q1 2026, up 7.59% year-on-year from $7.1 million in Q1 2025, and down 86.5% quarter-over-quarter from $56.7 million in Q4 2025.
Compugen (CGEN) Consolidated Net Income (2009 - 2026) Analysis & Trends
Compugen has disclosed Consolidated Net Income across 18 years of filings, most recently posting $7.7 million for Q1 2026.
- Consolidated Net Income for Q1 2026 came in at $7.7 million, up 7.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.9 million (up 772.34% YoY), and the FY2025 annual result was $35.3 million, up 348.35% from the prior year.
- Consolidated Net Income came in at $7.7 million for Q1 2026 at Compugen, down from $56.7 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $56.7 million in Q4 2025 to a low of -$28.0 million in Q2 2023.
- The 5-year median for Consolidated Net Income is -$3.1 million (2022), against an average of $1.4 million.
- Across the five-year window, Consolidated Net Income tumbled 198.03% in 2023 and jumped 1027.53% in 2025, its largest moves.
- Compugen's Consolidated Net Income stood at -$3.1 million in 2022, then surged by 414.13% to $9.7 million in 2023, then plunged by 162.98% to -$6.1 million in 2024, then surged by 1027.53% to $56.7 million in 2025, then tumbled by 86.5% to $7.7 million in 2026.
- The last three Consolidated Net Income figures came in at $7.7 million (Q1 2026), $56.7 million (Q4 2025), and -$6.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 56.74 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -21.61 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | -6.12 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | -16.62 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Dec 31, 2023 | 9.71 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | 9.31 Mn |
| Dec 31, 2022 | -3.09 Mn |
| Sep 30, 2022 | -11.75 Mn |
| Jun 30, 2022 | 28.56 Mn |
| Mar 31, 2022 | -9.71 Mn |
| Dec 31, 2021 | -8.65 Mn |
| Sep 30, 2021 | -8.18 Mn |
| Jun 30, 2021 | -9.50 Mn |